Skip to main content
SpringerLink
Log in

Management of Older Adults with Hypercholesterolaemia

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Although the strength of total cholesterol levels as a relative risk factor for coronary heart disease (CHD) declines with age, the prevalence of CHD increases dramatically with age. Data from cholesterol treatment trials, although sparse in older adults, suggest that dyslipidaemia treatment has the potential to prevent CHD. In particular, dyslipidaemia treatment appears to be most beneficial in older adults with a history of CHD or who have several other CHD risk factors.

Dyslipidaemia screening should be selective in the elderly, reserved for those whose health status would be amenable to nutritional or pharmacological therapy, and in whom several CHD risk factors or a history of CHD are present. Since high density lipoprotein cholesterol (HDL) levels retain their inverse association CHD in old age, cholesterol subfractions should be measured in persons being screened in order to adequately assess the severity of dyslipidaemia. Treatment decisions should be guided by the patient’s dyslipidaemic class, which is determined by the cholesterol subfractions and serum triglycerides (TG).

As in younger persons, nutritional therapy remains the first step in dyslipidaemia management in high risk, nondebilitated older adults. An array of cholesterol modifying medications are available which vary widely in treatment effects, adverse effects and cost. Extra care needs to be taken in prescribing these agents in older adults because of greater potential for adverse effects and interactions with other medications.

The cost-effectiveness of pharmacological treatment decreases with age and increases with the severity of dyslipidaemia, a history of CHD, or the presence of multiple CHD risk factors. When comparing elderly to middle-aged adults, the relative cost-effectiveness of different cholesterol-lowering medications may be altered due to age-related changes in therapeutic efficacy and adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • American College of Physicians. Guidelines for counselling postmenopausal women about preventive hormone therapy. Annals of Internal Medicine 117: 1038–1041, 1992

    Google Scholar 

  • Austin MA. Plasma triglyceride as a risk factor for coronary heart disease: the epidemiologic evidence and beyond. American Journal of Epidemiology 129: 249–259, 1989

    PubMed  CAS  Google Scholar 

  • Bach LA, Cooper ME, O’Brien RC, Jerums G. The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis. Journal of the American Geriatrics Society 38: 10–14, 1990

    PubMed  CAS  Google Scholar 

  • Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. Journal of the American Medical Association 265: 1861–1867, 1991

    Article  PubMed  CAS  Google Scholar 

  • Bates MC, Warren SG, Grubb S, Chillag S. Effectiveness of low-dose lovastatin in lowering serum cholesterol. Archives of Internal Medicine 150: 1947–1950, 1990

    Article  PubMed  CAS  Google Scholar 

  • Bradford RH, Shear CL, Chremos AN, Dujovne C, Downtown M, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: I. Efficacy in modifying lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Archives of Internal Medicine 151: 43–49, 1991

    Article  PubMed  CAS  Google Scholar 

  • Bush TL, Barrett-Conner E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 75: 1102–1109, 1987

    Article  PubMed  CAS  Google Scholar 

  • Castelli WP. The folly of questioning the benefits of cholesterol reduction. American Family Physician 49: 567–574, 1994

    PubMed  CAS  Google Scholar 

  • Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol. Lancet 2: 600–604, 1984

    Google Scholar 

  • Denke MA, Grundy SM. Hypercholesterolemia in elderly persons: resolving the treatment dilemma. Annals of Internal Medicine 112: 780–782, 1990

    PubMed  CAS  Google Scholar 

  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Journal of the American Medical Association 269: 3015–3023, 1993

    Article  Google Scholar 

  • Feely J, Coakley D. Altered pharmacodynamics in the elderly. Clinics in Geriatric Medicine 6: 269–283, 1990

    PubMed  CAS  Google Scholar 

  • Frick MH, Elo O, Haapa K, Heinonen MD, Heinsalmi P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New England Journal of Medicine 317: 1237–1245, 1987

    Article  PubMed  CAS  Google Scholar 

  • Genest J, Martin-Munley S, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 85: 2025–2033, 1992

    Article  PubMed  Google Scholar 

  • Goldman L, Gordon DJ, Rifkind BM, Hulley SB, Detsky AS, et al. Cost and health implications of cholesterol lowering. Circulation 85: 1959–1968, 1992

    Article  Google Scholar 

  • Grundy SM, Mok HYI, Zek L, Berman M. The influence of nicotinic acid on metabolism of cholesterol and triglyceride in man. Journal of Lipid Research 22: 24–31, 1981

    PubMed  CAS  Google Scholar 

  • Harris T, Cook EF, Kannel WB, Goldman L. Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 and older. Framingham Heart Study. Journal of the American Geriatrics Society 36: 1023–1028, 1988

    PubMed  CAS  Google Scholar 

  • Huff MW, Heidenheim P, Viswantha A, Burton H, Mills D, et al. Psyllium enhances the efficacy of colestipol in hypercholesterolemic subjects. Abstract. Circulation 86: 1–144, 1992

    Article  Google Scholar 

  • Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, et al. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. Journal of the American Medical Association 269: 3002–3008, 1993

    Article  PubMed  CAS  Google Scholar 

  • Kane JP, Malloy Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. Journal of the American Medical Association 264: 3007–3012, 1990

    Article  PubMed  CAS  Google Scholar 

  • Keenan JM, Bai CY, Fontaine PL, Wenz JB, Myers S, et al. Treatment of hypercholesterolemia: comparison of younger versus older patients using wax matrix sustained release niacin. Journal of the American Geriatrics Society 40: 12–18, 1991

    Google Scholar 

  • Knopp RH, Ginsberg J, Albers JJ, Hoff C, Oglivie JT, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 34: 642–650, 1985

    Article  PubMed  CAS  Google Scholar 

  • LaRosa JC, Cleeman JI. Cholesterol lowering as a treatment for established coronary heart disease. Circulation 85: 1229–1235, 1992

    Article  Google Scholar 

  • Laties AM, Shear CL, Lippa EA, Gould AL, Taylor HR, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: II. Assessment of the human lens after 48 weeks of treatment with lovastatin. American Journal of Cardiology 67: 447–453, 1991

    Article  PubMed  CAS  Google Scholar 

  • Levin EG, Miller VT, Muesing RA, Stoy DB, Balm TK, et al. Comparison of psyllium hydrophillic mucilloid and cellulose as adjuncts to a prudent diet in the treatment of mild to moderate hypercholesterolemia. Archives of Internal Medicine 150: 1822–1827, 1990

    Article  PubMed  CAS  Google Scholar 

  • Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. Journal of the American Medical Association 251: 351–364, 1984

    Article  Google Scholar 

  • Manninen V, Tenkanen L, Koskinen P, Huffunen JK, Manttari M, et al. Joint effects of serum triglyceride and LDL-cholesterol and HDL-cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation 85: 37–45, 1992

    Article  PubMed  CAS  Google Scholar 

  • Manolio TA, Furberg CD, Wahl PW, Tracy RP, Borhani NO, et al. Eligibility for cholesterol referral in community-dwelling older adults. Cardiovascular Health Study. Annals of Internal Medicine 116: 641–649, 1992

    PubMed  CAS  Google Scholar 

  • National Center for Health Statistics. Health, United States, 1991, Public Health Service, Hyattsville, Maryland, 1992

  • National Cholesterol Education Program Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Archives of Internal Medicine 148: 36–69, 1988

    Article  Google Scholar 

  • Nolan L, O’Malley K. Prescribing for the elderly. Part I. sensitivity of the elderly to adverse drug reactions. Journal of the American Geriatrics Society 36: 142–149, 1988

    PubMed  CAS  Google Scholar 

  • Oberman A, Kreisberg RA, Henkin Y. Principles and management of lipid disorders: a primary care approach. Williams & Wilkins, Baltimore, Maryland, 1992

    Google Scholar 

  • Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. Journal of Chronic Diseases 37: 201–206, 1978

    Google Scholar 

  • Psaty BM, Heckbert SR, Atkins D, Siskovick DS, Koepsell TD, et al. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Archives of Internal Medicine 153: 1421–1427, 1993

    Article  PubMed  CAS  Google Scholar 

  • Rifkind BM (Ed). Drug Treatment of Hyperlipidemia. Marcel Dekker, Inc. Publishers, New York, 1991

    Google Scholar 

  • Roussow JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. New England Journal of Medicine 323: 1112–1119, 1990

    Article  Google Scholar 

  • Rubin SM, Sidney S, Black DM, Browner WS, Hulley SB, et al. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Annals of Internal Medicine 113: 916–920, 1990

    PubMed  CAS  Google Scholar 

  • Schechtman G, Hiatt J, Hartz A. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium, and lovastatin) for treating hypercholesterolemia in veterans. American Journal of Cardiology 71: 759–765, 1993

    Article  Google Scholar 

  • The Surgeon General’s Report on Nutrition and Health. US Department of Health and Human Services, Public Health Service Publication No. 88-50211, 1988

  • Vine DL. Doubts about the clinical impact of cholesterol reduction. American Family Physician 49: 558–567, 1994

    PubMed  CAS  Google Scholar 

  • Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New England Journal of Medicine 325: 1196–1204, 1991

    Article  PubMed  CAS  Google Scholar 

  • Whelan AM, Price SO, Fowler SF, Hainer BL. The effect of aspirin on niacin-induced cutaneous reactions. Journal of Family Practice 34: 165–168, 1992

    PubMed  CAS  Google Scholar 

  • Yuen GJ. Altered pharmacokinetics in the elderly. Clinics in Geriatric Medicine 6: 257–268, 1990

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Family Practice and Community Health, University of Minnesota, 825 Washington Avenue, S.E., Minneapolis, Minnesota, 55414-3034, USA

    James T. Pacala

  2. School of Medicine and School of Pharmacy, University of Wisconsin, Madison, Wisconsin, USA

    Patrick E. McBride & Shelly L. Gray

Authors
  1. James T. Pacala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick E. McBride
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shelly L. Gray
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pacala, J.T., McBride, P.E. & Gray, S.L. Management of Older Adults with Hypercholesterolaemia. Drugs & Aging 4, 366–378 (1994). https://doi.org/10.2165/00002512-199404050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199404050-00002

Keywords

Search

Navigation